Connect with us

Stock Markets

AstraZeneca’s preventative COVID-19 shot shown to work longer-term

Published

on

2/2
AstraZeneca's preventative COVID-19 shot shown to work longer-term
© Reuters. FILE PHOTO: Vials labelled “Astra Zeneca COVID-19 Coronavirus Vaccine” and a syringe are seen in front of a displayed AstraZeneca logo, in this illustration photo taken March 14, 2021. REUTERS/Dado Ruvic

2/2

By Pushkala Aripaka and Ludwig Burger

(Reuters) -AstraZeneca on Thursday cemented its lead in bringing a preventative COVID-19 shot for the non-infected to market for people who do not respond well to vaccines, saying its antibody drug cocktail offered 83% protection over six months.

The therapy, called AZD7442 or Evusheld, had previously been shown to confer 77% protection against symptomatic illness after three months, in an earlier readout of the late-stage PROVENT trial in August.

The Anglo-Swedish company also said a separate study in patients with mild-to-moderate COVID-19 showed a higher dose of AZD7442 cut the risk of symptoms worsening by 88% when given within three days of first symptoms.

The treatment is given in one go, as two sequential shots in the arm.

The latest results from the longer-term follow-ups potentially position AstraZeneca (NASDAQ:), like rival Pfizer (NYSE:) as a future supplier of both COVID-19 vaccines and treatments, with AstraZeneca having said the therapy’s “real advantage” was as a preventative shot.

Pfizer has presented promising efficacy data on its oral COVID-19 treatment candidate, which can be more easily distributed than injections, and is also a leading vaccine supplier with partner BioNTech.

“These new data add to the growing body of evidence supporting AZD7442’s potential … We are progressing regulatory filings around the world and look forward to providing an important new option against SARS-CoV-2 as quickly as possible,” AstraZeneca Executive Vice President Mene Pangalos said in a statement, referring to the coronavirus that causes COVID-19.

The group last month sought approval for the medicine from U.S. and European authorities. Monoclonal antibodies from Regeneron (NASDAQ:), Lilly and GSK-Vir have been approved by U.S. regulators for treating unhospitalised COVID-19 patients.

LONG-TERM

For AstraZeneca’s PROVENT trial, close to 5,200 participants without an infection were randomly split into two groups, with one volunteer receiving an ineffective placebo without knowing for every two receiving Evusheld.

Participants were at risk of suffering severe COVID-19 if infected or were immunocompromised, meaning they were in cancer care, or receiving drugs due to an autoimmune disease or an organ transplant.

The trial volunteers were not vaccinated, even though high-risk groups have been prioritised in global vaccination campaigns. Anyone opting to get vaccinated during the trial was excluded from the analysis.

AstraZeneca has said the shot is primarily meant to help immunocompromised and at-risk individuals but at some point a wider group could benefit, such as military personnel on tours of duty or cruise ship passengers.

It added that about 2% of the global population was considered to inadequately respond to a COVID-19 vaccine.

Trial volunteers will be followed up for 15 months to provide evidence of longer-lasting protection.

Evusheld belongs to a drug category that is based on monoclonal antibodies which are lab-made proteins that mimic the body’s natural defences. They are based on antibodies that the human body produces in response to infection or vaccination.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Stock Markets

European stock indices are falling following Asian stock markets on Monday

Published

on

European stock indices are falling

Major European stock indices are falling under pressure from Asian markets, according to trading data and analyst commentary.

The British FTSE 100 index is down 0.71% to 7431.66 points, French CAC 40 is down 0.64% to 6667.31 points and German DAX is down 0.58% to 14456.82 points.

Why are European stock indices down? 

On Monday, investors’ attention was turned to the situation around the coronavirus in China. The country has seen a record surge in cases of coronavirus for several days in a row, and authorities have imposed a lot of new anti-coviral restrictions. As a result, Shanghai residents demonstrated on Sunday against the restrictions imposed by the authorities.

Against this backdrop, Asia-Pacific stock indexes ended Monday’s trading in the negative, which had an impact on the mood of traders in Europe.

“China will be the main driver today because any political instability in the country is a source of uncertainty and anxiety for markets,” Jaime Espejo, an equity fund manager at Imantia Capital in Madrid, told Bloomberg.

One of the main events for investors in Europe this week will be the statistical data on consumer prices in the euro area. Analysts think that, according to preliminary estimations, annual inflation slowed down to 10.4% from 10.6% in October.

Earlier we reported that the U.S. had banned imports of equipment by Huawei and several other companies from China.

Continue Reading

Stock Markets

Huawei is banned in the US: the US has banned the import of equipment from Huawei and several other companies from China

Published

on

huawei is banned in us

Huawei is banned in the US. The Federal Communications Commission for the first time recognized products of a lot of Chinese companies banned for import and sale because of national security risks. Commission member Carr said that China threatens U.S. interests through espionage.

Telecommunications and surveillance equipment manufactured by Huawei, ZTE, Hytera and several other Chinese companies are banned from importation and sale in the United States because of “unacceptable risks” to national security. This was announced by the Federal Communications Commission (FCC) on its website.

Huawei banned in the U.S. – what is banned?

The products of the subsidiaries and affiliates mentioned in the list of companies fall under the ban. Brendan Carr, a member of the Federal Communications Commission, called the decision unprecedented and unanimously adopted with the support of both parties in Congress. This is the first time in the history of the agency, he noted, that the distribution of communications and electronic equipment has been banned because of national security reasons.

Carr pointed out that “Communist China and other malevolent actors” are too eager to use loopholes in U.S. electronic systems to obtain sensitive information, they are trying to “compromise American interests through espionage, intellectual property theft, blackmail, foreign influence campaigns and other nefarious activities.”

Two years ago, the commission had already banned using government subsidies to buy equipment from Huawei and other Chinese companies, he recalled, and as a result many operators had refused to cooperate with such firms. But that decision left a loophole for buying equipment with private funds, and it’s time to close it, Carr said.

Huawei was put on U.S. sanctions lists more than three years ago, in May 2019. Washington accused the company of industrial espionage, stealing technology and threatening the U.S. economy. In February 2020, The Wall Street Journal, citing statements from U.S. officials, reported that Huawei had covert access to cell phone networks around the world.

The CIA believes Huawei was funded by Chinese intelligence, the Chinese Armed Forces and the Republic’s National Security Central Committee, sources told The Times. At the same time, the FBI believes that Huawei equipment installed on cellular towers near US military bases can jam and intercept Defense Department communications, including those used by the US Strategic Command, which is responsible for nuclear weapons.

Earlier, we reported that Bloomberg named the most profitable stock market in 2022.

Continue Reading

Stock Markets

What is the most profitable stock market? Bloomberg called it the most profitable stock market in 2022

Published

on

what is the most profitable stock market

What is the most profitable stock market? The stock market of Turkey, which is the most profitable stock market in the world, has become the growth leader this year, ahead of U.S., European and Asian platforms, Bloomberg wrote. The benchmark index Borsa Istanbul 100 (BIST 100) since the beginning of the year rose 78% in dollar terms.

In lira terms, the index, which includes shares of the 100 largest Turkish companies listed on the Istanbul Stock Exchange, has risen by more than 150% since January. This was the best result since 1999, the publication calculated. Most European financial markets have shown negative dynamics this year.

What is the most profitable stock market?

Turkey’s stock market hit an all-time high in November 2022 as private investors invested in Turkish assets to protect against high inflation. The Borsa Istanbul 100 index rose to a new record high of 4,784 points in trading on Nov. 16. During trading on Tuesday, Nov. 22, the BIST 100 index gained 3.6 percent to trade at 4,734 points.

Domestic investors are investing in stocks as Turkey’s central bank pursues a policy of lowering interest rates to spur economic growth, even as the country’s inflation rate exceeds 80 percent. Despite high inflation, the country’s regulator has conducted monetary policy easing cycles in 2021, which goes against current monetary policy. The rate cut has helped weaken the Turkish lira and turned equities into one of the few income-generating havens for investors.

Inflation in Turkey surpassed 85% in October for the first time in 25 years, and while the country’s central bank predicts it could fall to 65.2% by year’s end, price growth remains among the highest in the world.

Stocks have become favorites of Turkish investors. The number of stock trading accounts opened by private investors rose 32% this year to 3.1 million as of Nov. 18, according to Turkey’s Central Securities Depository.

According to Evren Kirikoglu, founder of Istanbul-based Sardis Research Consultancy, Turkish stocks are likely to remain attractive to investors for at least the first half of next year, even as inflation in the country begins to decline.

Earlier we reported that the U.S. stock market was up more than 1% for the day.

Continue Reading

Trending

©2021-2022 Letizo All Rights Reserved